The present study was designed to investigate a possible role of vanilloid receptors, CGRP and spleen in the induction of diabetes induced hyperalgesia in mice. Tail ‰ick latency, an index of hyperalgesia, was assessed using analgesiometer. Serum nitrite levels and an index of nitric oxide were analyzed using Griess reaction. Mice were rendered diabetic with streptozotocin (200 mg/kg -1 , i.p.) and kept for 30 days for development of diabetic pain. To explore the involvement of spleen in diabetic pain, spleen homogenate supernatant (SHS) was prepared from spleen of 30 th day diabetic mice and administered in normal mice for 14 days. Both in diabetic and SHS treated mice, signiˆcant degree of hyperalgesia was developed, suggesting the possible role of spleen derived factor in induction of diabetic pain. Moreover, the levels of nitric oxide were also elevated in 30 day diabetic mice and SHS treated mice. Administration of ruthenium red (1 mg/kg -1 , i.p.), vanilloid receptor antagonist, and sumatriptan (50 mg/kg -1 , i.p.), a CGRP release inhibitor, attenuated diabetes and SHS induced decrease in nociceptive threshold and increase in serum nitrite oxide levels. These results suggest that spleen derived factor induced activation of vanilloid receptors and CGRP release may be contributing in the development of hyperalgesia in diabetic mice.
INTRODUCTION
Diabetic patients frequently exhibit increased responsiveness to noxious stimuli (hyperalgesia) and hyper-responsiveness to normally innocuous stimuli (allodynia) that are often concurrent with a paradoxical loss of stimulus-evoked sensation. 1, 2) Similar to human diabetic pain, animal models such as streptozotocin (STZ) induced diabetic mice also demonstrate thermal hyperalgesia and mechanical allodynia. 3, 4) Transient receptor potential vanilloid (TRPV1) receptors are located on peripheral nerveˆbers and known to function as a molecular integrator of diŠer-ent painful stimuli. 5) Moreover, there have been reports indicating the involvement of TRPV1 receptors in development of in‰ammatory neuropathic pain. 6) Further, up-regulation of TRPV1 receptors has been reported in the development of nerve injury induced neuropathic pain. 7) The enhanced functioning of TRPV1 receptors in DRG neurons, probably due to increased phosphorylation, oligomerisation or reallocation of these receptors on the cell surface, may contribute to hyperalgesia in early stages of neuropathy. 8) Stimulation of TRPV1 receptors is associated with release of neuropeptides including calcitonin generelated peptide (CGRP) and induction of neurogenic in‰ammation. 9) Intrathecal administration of CGRP has been associated with decrease in mechanical and thermal nociceptive threshold. 10) Administration of a CGRP receptor antagonist has been reported to alleviate hyperalgesia in rodent model of neuropathy. 11) The basal as well as capsaicin evoked CGRP release has been shown to increase by two times during diabetic state. 12) Ruthenium red is reported to possess TRPV1 receptor antagonistic activities. 13) Sumatriptan is 5-HT 1B/1D agonist and inhibits presynaptic release of CGRP. 14) From our laboratory, it has been reported that spleenectomy restores the decrease in antinociceptive eŠect of morphine in diabetic mice, suggesting the interference of spleen factors with pain alteration during diabetes. 15) In the light of above, the present study was designed to investigate the role of vanilloid receptors, CGRP and spleen in the pathogenesis of diabetic neuropathic pain. , i.p.) was administered for induction of diabetes. Blood sample was obtained from retro-orbital sinus for glucose estimation. Mice with fasting blood glucose level of more than 14 mML -1 , on 16 th day after STZ administration, were considered diabetic and were included for further study. The diabetic mice were kept for further 14 days for development of diabetic hyperalgesia.
MATERIALS AND METHODS

Swiss
Estimation of Blood Glucose Blood glucose levels were estimated spectrophotometrically by glucoseoxidase method 16) using a commercially available enzymatic kit.
Measurement of Nociceptive Threshold Nociceptive threshold was determined by noting withdrawal latency in tail ‰ick test using tail ‰ick analgesiometer. 17) The intensity of the radiant heat was adjusted to obtain a basal or pre treatment latency of 6 8 s in normal mice. Maximum cut oŠ latency time wasˆxed at 10 s. Tail ‰ick latency was expressed in seconds.
Estimation of Serum Nitrite as an Index of Nitric Oxide Production
Nitric oxide is rapidly oxidized to nitrite/nitrate and its half-life in biological system is very short. 18) Therefore, the measurement of nitrite concentration is routinely used as an index of NO production. 19, 20) Serum nitrite levels were estimated by Griess reaction 21) and values were expressed in mmolL -1 .
Preparation of Spleen Homogenate
After sacriˆcing the mouse by cervical dislocation, spleen was removed and immersed in 1％ Minimal Essential Media (MEM, pH＝7.8). The spleen was mashed, homogenized, and centrifuged at 3000 r.p.m for 10 minutes. Spleen homogenate supernatant (SHS) was used in place of mononuclear spleen cells to avoid any implication of immunogenic response.
Experimental Design 8 groups, each comprising 6 animals, were included in the present study.
1) Control group Group I (n＝6): Mice were administered citrate buŠer to serve as non-diabetic control animals. Tail ‰ick latency was noted before and after administration of citrate buŠer on diŠerent days i.e. 0, 1, 4, 10, 14, 17, 20, 24 and 30 day. Serum nitrite levels were noted before and after 30 day of buŠer administration. Fasting glucose levels were monitored before and after administration of citrate buŠer on 0, 7, 14, 21, 28 and 30 day.
2) Streptozotocin (STZ) treated group Group II (n＝6): Mice were administered STZ (200 mg/kg -1 , i.p.) to serve as diabetic control animals. Tail ‰ick latency, serum nitrite and fasting glucose levels were noted on diŠerent days as described in group I.
3) Ruthenium red treated group Group III (n ＝6): Mice were administered ruthenium red (1 mg/kg -1 , i.p.), daily for 14 days, starting after 16 days of STZ administration. Tail ‰ick latency, serum nitrite and fasting glucose levels were noted on diŠer-ent days as described in group I. 4) Sumatriptan treated group Group IV (n＝ 6): Mice were administered sumatriptan (50 mg/kg -1 , i.p.), daily for 14 days, starting after 16 days of STZ administration. Tail ‰ick latency, serum nitrite and fasting glucose levels were noted on diŠer-ent days as described in group I. 5) Groups treated with spleen homogenate supernatant (SHS) (a) Group V (n＝6): Non-diabetic mice were administered normal saline solution 30 min prior to administration of SHS (1 ml/kg -1 , daily) of non-diabetic mice for 14 days. Tail ‰ick latency and blood glucose levels were noted on 0, 1, 2, 4, 8, 10 and 14 day of SHS administration. Serum nitrite levels were noted on 0 and 14 day after SHS administration.
(b) Group VI (n＝6): Non-diabetic mice were administered normal saline solution 30 min prior to administration of SHS of 30 day diabetic mice for 14 days and mice were evaluated as described in group V.
(c) Group VII (n＝6): Non-diabetic mice were administered ruthenium red (1 mg/kg -1 , i.p.), 30 min prior to administration of SHS of diabetic mice, for 14 days and mice were evaluated as described in group V. , i.p.), 30 min prior to administration of SHS of diabetic mice, for 14 days and mice were evaluated as described in group V.
Statistical Analysis All the results were expressed as mean ±S.E.M. Two way analysis of variance (ANOVA) was followed by the Tukey's multiple range test for post hoc analysis. The level of signiˆcance wasˆxed at p＜0.05.
RESULTS
EŠect of Pharmacological Agents on Blood Glucose Level
Signiˆcant rise in glucose levels was noted in STZ treated mice as compared to citrate buŠer treated mice. Neither ruthenium red nor sumatriptan modulated STZ induced rise in glucose levels. Administration of SHS of diabetic mice did not aŠect basal glucose levels. Moreover, ruthenium red and sumatriptan also did not modulate glucose levels in SHS treated mice ( Table 1) .
EŠect of Diabetes on Tail Flick Latency Time
In streptozotocin rendered diabetic mice, there was signiˆcant decrease in tail ‰ick latency time as compared to mice treated with citrate buŠer. The increase in pain sensitivity re‰ects diabetes induced changes in non-myelinated nerveˆbers, which transmit pain sensation of heat. This decrease in latency time was directly related to duration of diabetes and was more pronounced after 20 days of STZ administration (Fig. 1) .
EŠect of Pharmacological Interventions on Tail Flick Latency Time in Diabetic Mice
Administration of ruthenium red (1 mg/kg , i.p.), attenuated diabetes induced decrease in tail ‰ick latency time, noted on diŠerent days (Fig. 1) .
EŠect of Pharmacological Interventions on Serum Nitrite Level in Diabetic Mice
Serum nitrite levels were increased signiˆcantly in diabetic mice as compared to normal non-diabetic mice. However, administration of ruthenium red and sumatriptan attenuated diabetes induced increase in serum nitrite levels in a signiˆcant manner (Fig. 2) .
EŠect of SHS on Tail Flick Latency Time and Serum Nitrite Levels
Administration of SHS of non-diabetic mice did not produce any signiˆcant eŠect on tail ‰ick latency time and serum nitrite levels in normal mice (Figs. 3 and 4) . However, administration of SHS of 30 th day diabetic mice signiˆcantly decreased tail ‰ick latency time and increased serum nitrite levels in normal mice (Figs. 3 and 4) .
EŠect of Spleen Homogenate Supernatant (SHS) on Normal Mice Treated with Ruthenium Red and Sumatriptan
Ruthenium red and sumatriptan signiˆcantly attenuated SHS of 30 th day diabetic mice induced decrease in tail ‰ick latency and increased serum nitrite levels (Figs. 3 and 4) .
DISCUSSION
Streptozotocin (STZ) is well reported chemical agent to induce insulin dependent diabetes mellitus (IDDM) in mice. It is reported from our studies 15, 19) as well as from other laboratories 3) that signiˆcant degree of hyperalgesia develops in mice after 4 weeks of STZ administration. Therefore, mice were kept for 4 weeks after STZ administration to provide su‹cient time for hyperglycemia to aŠect pain perception. Nitric oxide is rapidly oxidized to nitrite/nitrate and its half-life in biological system is very short. 20) Therefore, the measurement of nitrite concentration is routinely used as an index of NO production. 21, 22) In the present study, pain threshold was decreased signiˆcantly in STZ rendered diabetic mice. However, administration of ruthenium red, a TRPV1 receptor antagonist, and sumatriptan, a CGRP release inhibitor, resulted in attenuation of diabetes induced decrease in pain threshold. The noted anti-nociceptive actions of TRPV1 antagonist and CGRP release inhibitor indicate the key role of TRPV1 and CGRP in the induction of diabetic neuropathic pain. TRPV1 receptors are reported to be involved in induction of pain in tissue injury and in‰ammation. 23, 24) Moreover, these receptors are also reported to be up-regulated in nerve injury induced neuropathic pain. 7) TRPV1 receptor antagonist, resiniferatoxin, has been demonstrated to prevent the development of hyperalgesia produced by ligation of sciatic nerve. 25) CGRP plays an important role in pain signal transmission and CGRP antagonist has been reported to alleviate hyperalgesia in rodent model of neuropathic pain. 11) Moreover, cizolirtine has been reported to attenuate diabetic neuropathic pain through presynaptic inhibition of CGRP release. 27) Furthermore, activation of TRPV1 is associated with release of CGRP. 24) So, it may be tentatively proposed that CGRP release triggered by TRPV1 activation is contributing in inducing hyperalgesia in diabetes.
In the present investigation, the serum nitrite levels were signiˆcantly elevated after 30 days of STZ administration. These results are in consonance with report from our laboratory 19) and from others. 28) In the previous study from our laboratory, it was reported that aminoguanidine, a nitric oxide synthase inhibitor, attenuated diabetes induced increased levels of nitric oxide along with decrease in tail ‰ick latency. 19) Serum nitrite levels are indicative of nitric oxide produced from eNOS (endothelium), not from nNOS synthase (neurons). So, the noted rise in serum nitrite levels in the present investigation suggests the enhanced expression of eNOS. Moreover, it has been documented that increase in nNOS is not responsible for diabetic neuropathy pain, 29) while its decreased expression may do so. 30) Further, it has also been noticed that net nitric oxide concentration is reduced during diabetes. Perhaps, this may be the re‰ective of diŠerential eŠect of diabetes on expression of nNOS and eNOS. However, this paradoxical eŠect of diabetes on nitric oxide needs further research. Administration of ruthenium red and sumatriptan attenuated diabetes induced increase in serum nitrite levels. It may be probably due to blockade of TRPV1 receptors and CGRP mediated nitric oxide release. 31, 32) In the present investigation, administration of spleen homogenate supernatant (SHS) of 30 th day diabetic mice resulted in induction of hyperalgesia in normal non-diabetic mice. These results suggest that certain factors are released from spleen during diabetes, which contribute signiˆcantly in induction of hyperalgesia. However, administration of ruthenium red and sumatriptan attenuated SHS induced decrease in pain threshold. Although, the nature of spleen derived factors was not investigated, yet these results tentatively suggest that these factors activate TRPV1 receptors, release CGRP and induce hyperalgesia. Further, serum nitrite levels were also elevated as a consequence of SHS administration. Moreover, TRPV1 receptor antagonist and CGRP release inhibitor attenuated SHS induced elevated serum nitrite levels suggesting the inter-relationship of TRPV1, CGRP, spleen derived factor, nitric oxide and diabetic hyperalgesia. Nevertheless, further studies are needed for more conclusive evidence regarding this hypothesis by employing NO synthase inhibitor and capsaicin on SHS eŠect.
CONCLUSIONS
It may be concluded that spleen derived factors are contributing in the induction of diabetic hyperalgesia probably through the activation of vanilloid receptors, release of CGRP and nitric oxide. Nevertheless, further studies are required to elucidate the nature of spleen derived factor and inter-relationship between the contributing factors involved in induction of hyperalgesia due to diabetes.
